09-08-02 Box SE 1

[UTILI]TY PATENT APPLICATION TRANSMITTAL
(for [n]onprovisional applications under 37 CFR 1.53(b))

Attorney Docket B45069-1

First Named Inventor or Application Identifier
Jean-Francois Lucien Maisonneuve

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents.

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570
   ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))
   (Submit an original, and a duplicate for fee processing)

2. ☒ The total fee is calculated as shown below:
Basic Filing fee	$690.00
Total Claims 17 - 20 = 0 x $18	$ 0.00
Independent Claims 2 - 3 = 0 x $78	$ 0.00
☒ Multiple Dependent Claim present. $260	$260.00
TOTAL FILING FEE	$950.00

   ☐ Cancel in this application original claims __to __ of the prior application before calculating the filing fee.
   ☒ Charge $950.00 to the above indicated Deposit Account.

3. ☒ Specification excluding Drawings [*Total Pages*] 42

4. ☐ Drawing(s) (35 USC 113) [*Total Sheets*] _____

5. ☒ Declaration and Power of Attorney [*Total Pages*] 3
   a. ☐ Newly executed (original or copy)
   b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional with Box 17a completed)*
   c. ☒ Unsigned Declaration [*Note Box 6 below*]
      i. ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. ☐ Incorporation By Reference *(useable if Box 5b is checked)*
   The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

7. ☒ The Title of the Invention:
   Vaccines

8. ☒ Nucleotide and/or Amino Acid Sequence Submission
   a. ☒ Computer Readable Copy
   b. ☒ Paper Copy (identical to computer copy)
   c. ☒ Statement verifying identity of above copies
   d. ☐ Use the identical computer-readable form filed in Application No. _____, filed ___ __ as the computer-readable form for the instant application. (37 CFR 1.821(e))

ACCOMPANYING APPLICATION PARTS
9. a. ☒ Information Disclosure Statement (IDS)
   b. ☒ PTO-1449
   c. ☒ Copies of all IDS Citations

10. ☐ Assignment Papers (cover sheet & document(s))

11. ☒ Prior Application is Assigned to:
   SmithKline Beecham Biologicals, sa
   (for continuation/divisional with Box 17a completed

12. ☐ Preliminary Amendment [*Total Pages*]

13. ☒ Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*

14. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

15. ☐ Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. _____ filed _____. A PTO-1449 listing the references is enclosed.

16. ☐ Other: _____

17. ☒ **Priority Information**, *check appropriate box and supply the requisite information*
a. The accompanying application is a ☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No: 08/930,729 filed March 19, 1998 and application No. 09/331,533 filed June 23, 1999.
b. ☐ Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. _____ filed .
c. ☐ Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78)
   This is a continuation/divisional of application Serial No. _____ filed _____.

18. CORRESPONDENCE ADDRESS
Address
SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939

Telephone (610) 270-5024   **Fax** (610) 270-5090

19. RESPECTFULLY SUBMITTED,
Signature
Name   Zoltan Kerekes

Registration No.   38,938

N:\zk\apps\b45069-1\UTILITY PATENT APPLICATION.doc